Aerogen, Lyomark ink inhaled surfactant deal


Aerogen, LyomarkAerogen and Lyomark Pharma said today that they inked a deal to develop an inhaled surfactant treatment for respiratory distress syndrome in pre-term infants.

The pact calls for the duo to combine a compound called AP-002, a nasally inhaled surfactant based on a combination of Lyomark’s Alveofact bovine lung surfactant and Aerogen’s PDAP nasal delivery technology. Aerogen will develop the drug-device combo and the companies will cooperate on commercialization and distribution, they said.

Get the full story at our sister site, Drug Delivery Business News.